Viveve Medical (VIVE) 10-Q 10 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 09, 2017
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		19,405,334
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	[1]
Current assets:
Cash and cash equivalents	$ 31,060	$ 8,086
Accounts receivable	3,800	2,091
Inventory	2,043	2,687
Prepaid expenses and other current assets	1,888	1,066
Total current assets	38,791	13,930
Property and equipment, net	987	483
Other assets	132	136
Total assets	39,910	14,549
Current liabilities:
Accounts payable	3,344	3,086
Accrued liabilities	2,181	2,186
Note payable, current portion		1,867
Total current liabilities	5,525	7,139
Note payable, noncurrent portion	18,392	7,762
Other noncurrent liabilities		53
Total liabilities	23,917	14,954
Commitments and contingences (Note 6)
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2017 and December 31, 2016; no shares issued
Common stock, $0.0001 par value; 75,000,000 shares authorized as of June 30, 2017 and December 31, 2016; 19,405,334 and 10,661,201 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	2	1
Additional paid-in capital	101,733	68,216
Accumulated deficit	(85,742)	(68,622)
Total stockholders’ equity (deficit)	15,993	(405)
Total liabilities and stockholders’ equity (deficit)	$ 39,910	$ 14,549
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	19,405,334	10,661,201
Common stock, shares outstanding (in shares)	19,405,334	10,661,201

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue	$ 3,076	$ 1,556	$ 6,117	$ 2,840
Cost of revenue	1,837	1,022	3,456	1,958
Gross profit	1,239	534	2,661	882
Operating expenses:
Research and development	3,440	2,463	5,828	4,259
Selling, general and administrative	6,862	2,615	12,312	5,163
Total operating expenses	10,302	5,078	18,140	9,422
Loss from operations	(9,063)	(4,544)	(15,479)	(8,540)
Interest expense, net	(1,345)	(765)	(1,608)	(873)
Other expense, net	(17)	(7)	(33)	(9)
Comprehensive and net loss	$ (10,425)	$ (5,316)	$ (17,120)	$ (9,422)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.54)	$ (0.66)	$ (1.10)	$ (1.21)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	19,373,322	8,080,737	15,539,840	7,786,889

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017		Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (17,120)		$ (9,422)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	188		45
Stock-based compensation	827		390
Fair value of common stock issued	260
Fair value of warrants issued			162
Non-cash interest expense	489		387
Changes in assets and liabilities:
Accounts receivable	(1,709)		4
Inventory	352		679
Prepaid expenses and other current assets	(822)		24
Other noncurrent assets	4		(1)
Accounts payable	258		422
Accrued and other liabilities	(58)		1,009
Net cash used in operating activities	(17,331)		(6,301)
Cash flows from investing activities:
Purchase of property and equipment	(400)		(137)
Net cash used in investing activities	(400)		(137)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	31,440		13,857
Proceeds from note payable, net of issuance costs	19,214		9,944
Repayments of note payable	(10,000)		(4,833)
Proceeds from exercise of warrant	20		27
Proceeds from exercise of stock options	31		14
Net cash provided by financing activities	40,705		19,009
Net increase in cash and cash equivalents	22,974		12,571
Cash and cash equivalents - beginning of period	8,086	[1]	7,360
Cash and cash equivalents - end of period	31,060		19,931
Supplemental disclosure:
Cash paid for interest	1,183		487
Cash paid for income taxes			1
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrants in connection with note payable	940		350
Net transfer of equipment between inventory and property and equipment	292		25
Restricted stock awards granted to employees for 2015 accrued bonuses			$ 246
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s health industry in some countries by marketing Geneveve™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Public Offering On March 22, 2017, “March 2017 8,625,000 $4.00 $34,500,000. $31,440,000. March 2017 10 December 31, 2016, no On June 17, 2016, “June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. Change of Corporate Domicile On May 9, 2016, May 10, 2016, $0.0001 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2016, February 16, 2017. three six June 30, 2017 not December 31, 2017

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no The Company’s products likely require clearance or approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that it refers to as Geneveve™. Geneveve includes three third In the U.S., the Company sells its products primarily through a direct sales force to health care practitioners. Outside the U.S., the Company sells through an extensive network of distribution partners. During the three June 30, 2017, three 37% three June 30, 2016, two 92% six June 30, 2017, two 26% six June 30, 2016, two 75% There were no 10% three six June 30, 2017 2016. As of June 30, 2017, four 65% December 31, 2016, three 81% Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Product Warranty The Company’s products are generally subject to a one not Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three six June 30, 2017 2016, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Six Months Ended June 30, 2017 2016 Stock options to purchase common stock 2,287,572 1,126,287 Warrants to purchase common stock 642,622 506,379 Restricted common stock awards 6,250 39,494 Recently Issued and Adopted Accounting Standards In May 2014, 2014 09, 606 five not December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 ( 2015 14 2016 08 2016 10 2016 10 May 2016, 2016 12, 606 not May 2014. In February 2016, 2016 02, 842 December 15, 2018, In August 2016, No. 2016 15, 230 zero December 15, 2017, We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no June 30, 2017 December 31, 2016. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of June 30, 2017 December 31, 2016

Note 4 - Accrued Liabilities

Note 4 - Accrued Liabilities	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued liabilities consisted of the following (in thousands): June 30, December 31, 2017 2016 Accrued professional fees $ 677 $ 483 Accrued payroll and other related expenses 660 389 Accrued bonuses 585 1,102 Accrued sales and use tax 83 39 Accrued interest - 65 Other accruals 176 108 Total accrued liabilities $ 2,181 $ 2,186

Note 5 - Note Payable

Note 5 - Note Payable	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	5. On June 20, 2016, January 13, 2017 ( “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2016 4.00% 2016 May 2017. In connection with the 2016 10 100,402 $4.98 7 On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 September 17, 2018, $16,000,000 twelve 12 June 30, 2018 $60,000,000 thirty 30 second A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its existing 2016 2017 may The 2017 six four 2017 12.50%, 4.0% may, three June 30, 2017, $80,000 June 30, 2017. 5% The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 In connection with the 2017 two 10 222,049 $9.50 7 As of June 30, 2017, Year Ending December 31, 2017 (remaining 6 months) $ 877 2018 1,793 2019 1,867 2020 1,949 2021 11,204 Thereafter 17,154 Total payments 34,844 Less: Amount representing interest (14,764 ) Present value of obligations 20,080 Less: Unamortized debt discount (1,688 ) Note payable, noncurrent portion $ 18,392

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	6. Operating Lease In January 2012, September 2016, March 2012 March 2018. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three June 30, 2017 2016 $94,000 $54,000, six June 30, 2017 2016 $167,000 $109,000, As of June 30, 2017, Year Ending December 31, 2017 (remaining 6 months) $ 289 2018 338 2019 264 2020 113 Total minimum lease payments $ 1,004 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding in considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 7 - Common Stock

Note 7 - Common Stock	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. On May 19, 2017, 35,000 $7.42 $260,000. On March 22, 2017, March 2017 8,625,000 $4.00 $34,500,000. $31,440,000. On June 17, 2016, June 2016 3,105,000 $5.00 $15,525,000. $13,886,000. Warrants for Common Stock As of June 30, 2017, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 In connection with the Loan and Security Agreement entered into on September 30, 2014, February 19, 2015, May 14, 2015, November 30, 2015 March 18, 2016 ( “2014 1 58,962 $4.24 June 2016 2016 June 30, 2016. three six June 30, 2016, $342,000 $387,000, August 2016. In connection with the 2016 100,402 $4.98 $350,000. $90,000, May 2017 2017 three June 30, 2017. three six June 30, 2017, $336,000 $371,000 three six June 30, 2016, no June 30, 2017, 2016 In connection with the 2017 222,049, $9.50 ten $940,000 0%, 55.1%, 2.25% ten $786,000, three six June 30, 2017, $38,000 June 30, 2017, $1,688,000. A total of 4,701 6,250 September 30, 2014, six June 30, 2017 2016, No six June 30, 2017. 1,094 two October 2014 six June 30, 2016 not The stock-based compensation expense related to warrants issued was zero $20,000 three June 30, 2017 2016, zero $118,000 six June 30, 2017 2016,

Note 8 - Summary of Stock Optio

Note 8 - Summary of Stock Options	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8 Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards from three 2005 “2005 2006 “2006 2013 “2013 The 2005 June 30, 2017, 1,892 2005 not 2005 2005 2005 1,892 $116.29 0.23 The 2006 September 23, 2014 2006 2006 2006 38,378 no $10.49 5.38 The 2013 2013 2013 may may may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, 2013 2013 first January, 2013 4% December 23, 2016, 2017 2013 523,209 2,000,000 2,523,209 January 1, 2017. June 30, 2017, 2013 2,247,302 143,110 $5.98 8.89 Activity under the 2005 2006 2013 Six Months Ended June 30, 2017 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 420,985 $ 5.88 Options exercised (7,730 ) $ 4.02 Options cancelled (35,447 ) $ 5.64 Options outstanding, end of period 2,287,572 $ 6.15 8.82 $ 3,290,039 Vested and exercisable and expected to vest, end of period 2,135,320 $ 6.17 8.79 $ 3,076,175 Vested and exercisable, end of period 603,985 $ 6.83 7.94 $ 935,383 The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of June 30, 2017. The options outstanding and exercisable as of June 30, 2017 Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices June 30, 2017 Price Term (Years) June 30, 2017 Price $2.64 12,500 $ 2.64 7.87 6,771 $ 2.64 $3.68 - $3.76 66,876 $ 3.76 7.61 39,011 $ 3.76 $4.46 - $4.92 427,829 $ 4.62 8.58 141,577 $ 4.78 $5.22 586,409 $ 5.22 9.48 75,491 $ 5.22 $6.00 557,753 $ 6.00 8.47 209,161 $ 6.00 $6.24 - $6.40 117,965 $ 6.35 8.34 43,466 $ 6.35 $7.00 - $7.92 472,325 $ 7.67 9.36 42,593 $ 7.70 $9.92 38,135 $ 9.92 5.40 38,135 $ 9.92 $56.00 - $296.00 7,780 $ 83.66 0.33 7,780 $ 83.66 2,287,572 $ 6.15 8.82 603,985 $ 6.83 Restricted Stock Awards In January 2016, 39,494 2013 2015 $6.24 89 September 2016. one January 2017 39,405 In August 2016, 5,998 2013 $7.89 5,998 In September 2016, 25,000 $7.58 one 1/4 th June 30, 2017, 18,750 In November 2016, 6,544 2013 $5.91 6,544 In May 2017, 4,797 2013 $7.07 4,797 The total number of shares pursuant to outstanding RSAs as of June 30, 2017 6,250 Stock-Based Compensation During the three June 30, 2017 2016, 185,250 28,750 $3.31 $3.17 six June 30, 2017 2016, 415,110 158,017 $2.56 $3.49 7,730 3,020 six June 30, 2017 2016, six June 30, 2017 2016 $30,785 $5,000, The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Expected term (in years) 5 5 5 5 Average volatility 48 % 47 % 48 % 65 % Risk-free interest rate 1.76 % 1.26 % 1.90 % 1.53 % Dividend yield 0 % 0 % 0 % 0 % During the three six June 30, 2017, 5,875 $5.11 three six June 30, 2016, no no six June 30, 2017 2016. Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three six June 30, 2017 2016 Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Cost of revenue $ 4 $ - $ 7 $ - Research and development 57 28 108 49 Selling, general and administrative 394 174 712 341 Total $ 455 $ 202 $ 827 $ 390 As of June 30, 2017, $4,109,000. 3.04

Note 9 - Income Taxes

Note 9 - Income Taxes	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0 three six June 30, 2017 2016. 2017 0%.

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	10. In June 2006, October 4, 2007. 300 June 30, 2017, 415 37,500 $1,681,000 $945,000 three June 30, 2017 2016, $3,706,000 $2,160,000 six June 30, 2017 2016, June 30, 2017 December 31, 2016 $637,000 $1,297,000,

Note 11 - Subsequent Events

Note 11 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	11. On August 8, 2017, $2,500,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no The Company’s products likely require clearance or approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, and for vaginal rejuvenation, depending on the relevant country-specific clearance or approval, that it refers to as Geneveve™. Geneveve includes three third In the U.S., the Company sells its products primarily through a direct sales force to health care practitioners. Outside the U.S., the Company sells through an extensive network of distribution partners. During the three June 30, 2017, three 37% three June 30, 2016, two 92% six June 30, 2017, two 26% six June 30, 2016, two 75% There were no 10% three six June 30, 2017 2016. As of June 30, 2017, four 65% December 31, 2016, three 81%
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon shipment, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. The Company does not
Customer Advance Payments, Policy [Policy Text Block]	Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to a one not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three six June 30, 2017 2016,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Six Months Ended June 30, 2017 2016 Stock options to purchase common stock 2,287,572 1,126,287 Warrants to purchase common stock 642,622 506,379 Restricted common stock awards 6,250 39,494
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, 2014 09, 606 five not December 15, 2017. January 1, 2017 January 1, 2018, January 1, 2017 ( 2015 14 2016 08 2016 10 2016 10 May 2016, 2016 12, 606 not May 2014. In February 2016, 2016 02, 842 December 15, 2018, In August 2016, No. 2016 15, 230 zero December 15, 2017, We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa18

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Six Months Ended June 30, 2017 2016 Stock options to purchase common stock 2,287,572 1,126,287 Warrants to purchase common stock 642,622 506,379 Restricted common stock awards 6,250 39,494

Note 4 - Accrued Liabilities (T

Note 4 - Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, December 31, 2017 2016 Accrued professional fees $ 677 $ 483 Accrued payroll and other related expenses 660 389 Accrued bonuses 585 1,102 Accrued sales and use tax 83 39 Accrued interest - 65 Other accruals 176 108 Total accrued liabilities $ 2,181 $ 2,186

Note 5 - Note Payable (Tables)

Note 5 - Note Payable (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2017 (remaining 6 months) $ 877 2018 1,793 2019 1,867 2020 1,949 2021 11,204 Thereafter 17,154 Total payments 34,844 Less: Amount representing interest (14,764 ) Present value of obligations 20,080 Less: Unamortized debt discount (1,688 ) Note payable, noncurrent portion $ 18,392

Note 6 - Commitments and Cont21

Note 6 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2017 (remaining 6 months) $ 289 2018 338 2019 264 2020 113 Total minimum lease payments $ 1,004

Note 7 - Common Stock (Tables)

Note 7 - Common Stock (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 8 - Summary of Stock Opt23

Note 8 - Summary of Stock Options (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Six Months Ended June 30, 2017 Weighted Weighted Average Aggregate Number Average Remaining Intrinsic of Exercise Contractual Value Shares Price Term (years) (in thousands) Options outstanding, beginning of period 1,909,764 $ 6.19 9.12 $ 211,396 Options granted 420,985 $ 5.88 Options exercised (7,730 ) $ 4.02 Options cancelled (35,447 ) $ 5.64 Options outstanding, end of period 2,287,572 $ 6.15 8.82 $ 3,290,039 Vested and exercisable and expected to vest, end of period 2,135,320 $ 6.17 8.79 $ 3,076,175 Vested and exercisable, end of period 603,985 $ 6.83 7.94 $ 935,383
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices June 30, 2017 Price Term (Years) June 30, 2017 Price $2.64 12,500 $ 2.64 7.87 6,771 $ 2.64 $3.68 - $3.76 66,876 $ 3.76 7.61 39,011 $ 3.76 $4.46 - $4.92 427,829 $ 4.62 8.58 141,577 $ 4.78 $5.22 586,409 $ 5.22 9.48 75,491 $ 5.22 $6.00 557,753 $ 6.00 8.47 209,161 $ 6.00 $6.24 - $6.40 117,965 $ 6.35 8.34 43,466 $ 6.35 $7.00 - $7.92 472,325 $ 7.67 9.36 42,593 $ 7.70 $9.92 38,135 $ 9.92 5.40 38,135 $ 9.92 $56.00 - $296.00 7,780 $ 83.66 0.33 7,780 $ 83.66 2,287,572 $ 6.15 8.82 603,985 $ 6.83
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Expected term (in years) 5 5 5 5 Average volatility 48 % 47 % 48 % 65 % Risk-free interest rate 1.76 % 1.26 % 1.90 % 1.53 % Dividend yield 0 % 0 % 0 % 0 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Cost of revenue $ 4 $ - $ 7 $ - Research and development 57 28 108 49 Selling, general and administrative 394 174 712 341 Total $ 455 $ 202 $ 827 $ 390

Note 1 - The Company and Basi24

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Mar. 22, 2017	Jun. 17, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	May 10, 2016
Proceeds from Issuance of Common Stock			$ 31,440,000	$ 13,857,000
Common Stock, Par or Stated Value Per Share			$ 0.0001		$ 0.0001	$ 0.0001
March 2017 Offering [Member]
Proceeds From Issuance of Common Stock, Net	$ 31,440,000
Stock Issued During Period, Shares, New Issues	8,625,000
Share Price	$ 4
Proceeds from Issuance of Common Stock	$ 34,500,000
June 2016 Offering [Member]
Proceeds From Issuance of Common Stock, Net		$ 13,886,000
Stock Issued During Period, Shares, New Issues		3,105,000
Share Price		$ 5
Proceeds from Issuance of Common Stock		$ 15,525,000

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Warranty Period			1 year
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	37.00%	92.00%	26.00%	75.00%
Concentration Risk, Number of Customers	3	2	2	2
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage			65.00%		81.00%
Concentration Risk, Number of Customers			4		3

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,287,572	1,126,287
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	642,622	506,379
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	6,250	39,494

Note 4 - Accrued Liabilities -

Note 4 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued professional fees	$ 677	$ 483
Accrued payroll and other related expenses	660	389
Accrued bonuses	585	1,102
Accrued sales and use tax	83	39
Accrued interest		65
Other accruals	176	108
Total accrued liabilities	$ 2,181	$ 2,186	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 5 - Note Payable (Details

Note 5 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Jun. 20, 2016	May 31, 2017	Jun. 30, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				642,622
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.98		$ 4.98
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Number of Warrants Issued During Period	2
Warrant Term	10 years		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049		222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50		$ 9.50	$ 9.50
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount		$ 10,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt		$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt		$ 2,500,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Agreement, Covenant, Additional Funding	$ 10,000,000
Debt Agreement, Maximum Borrowing Capacity	30,000,000
Debt Instrument, Covenant, Additional Funding, Minimum Net Revenue	16,000,000
Debt Instrument, Covenant, Additional Funding, Minimum Average Market Capitalization	$ 60,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest				$ 80,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000
Debt Instrument, Face Amount	$ 20,000,000

Note 5 - Note Payable - Summary

Note 5 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	[1]
2017 (remaining 6 months)	$ 877
2,018	1,793
2,019	1,867
2,020	1,949
2,021	11,204
Thereafter	17,154
Total payments	34,844
Less: Amount representing interest	(14,764)
Present value of obligations	20,080
Less: Unamortized debt discount	(1,688)
Note payable, noncurrent portion	$ 18,392	$ 7,762
[1]	The condensed consolidated balance sheet as of December 31, 2016 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Commitments and Cont30

Note 6 - Commitments and Contingencies (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Feb. 01, 2017USD ($)ft²$ / item
Operating Leases, Rent Expense | $	$ 94,000	$ 54,000	$ 167,000	$ 109,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²					12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item					20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item					21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item					21.75
Security Deposit | $					$ 22,000
Operating Leases, Allowance for Certain Improvements | $					$ 88,000

Note 6 - Commitments and Cont31

Note 6 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2017USD ($)
2017 (remaining 6 months)	$ 289
2,018	338
2,019	264
2,020	113
Total minimum lease payments	$ 1,004

Note 7 - Common Stock (Details

Note 7 - Common Stock (Details Textual) - USD ($)	May 31, 2017	May 22, 2017	Mar. 22, 2017	Jun. 20, 2016	Jun. 17, 2016	May 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2014
Proceeds from Issuance of Common Stock									$ 31,440,000	$ 13,857,000
Debt Instrument, Unamortized Discount							$ 1,688,000		$ 1,688,000
Class of Warrants or Rights, Exercises in Period									4,701	6,250
Allocated Share-based Compensation Expense							$ 455,000	$ 202,000	$ 827,000	$ 390,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							642,622		642,622
The 2016 Loan Agreement [Member]
Debt Issuance Costs, Net							$ 90,000		$ 90,000
Amortization of Debt Discount (Premium)							336,000	0	371,000	0
The 2017 Loan Agreement [Member]
Debt Instrument, Unamortized Discount							1,688,000		1,688,000
Debt Issuance Costs, Net	$ 786,000					$ 786,000
Amortization of Debt Discount (Premium)							38,000		38,000
September 2014 Issuance Related to 2014 Loan Agreement [Member]
Amortization of Debt Discount (Premium)								342,000		387,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											58,962
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 4.24
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Unamortized Debt Issuance Expense							$ 0		$ 0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				100,402			100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 4.98			$ 4.98		$ 4.98
Warrant Term				10 years
Warrants and Rights Outstanding				$ 350,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Allocated Share-based Compensation Expense							$ 0	$ 20,000	$ 0	$ 118,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049	222,049				222,049	222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50	$ 9.50				$ 9.50	$ 9.50		$ 9.50
Warrant Term		10 years				10 years
Warrants and Rights Outstanding	$ 940,000					$ 940,000
Fair Value Assumptions, Expected Dividend Rate						0.00%
Fair Value Assumptions, Expected Volatility Rate						55.10%
Fair Value Assumptions, Risk Free Interest Rate						2.25%
Fair Value Assumptions, Expected Term	10 years
Vendors and Contractors Warrants, October and November 2014 Issuance [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period									0	1,094
March 2017 Offering [Member]
Proceeds From Issuance of Common Stock, Net			$ 31,440,000
Stock Issued During Period, Shares, New Issues			8,625,000
Share Price			$ 4
Proceeds from Issuance of Common Stock			$ 34,500,000
June 2016 Offering [Member]
Proceeds From Issuance of Common Stock, Net					$ 13,886,000
Stock Issued During Period, Shares, New Issues					3,105,000
Share Price					$ 5
Proceeds from Issuance of Common Stock					$ 15,525,000
Restricted Stock [Member]
Shares Issued, Price Per Share	$ 7.42					$ 7.42
Stock Issued During Period, Value, New Issues						$ 260,000
Stock Issued During Period, Shares, New Issues						35,000

Note 7 - Common Stock - Summary

Note 7 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017	May 31, 2017	May 22, 2017	Jun. 20, 2016
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98			$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402			100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049	222,049

Note 8 - Summary of Stock Opt34

Note 8 - Summary of Stock Options (Details Textual) - USD ($)	Dec. 23, 2016	Aug. 22, 2016	May 31, 2017	Jan. 31, 2017	Nov. 30, 2016	Sep. 30, 2016	Aug. 31, 2016	Jan. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 22, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									2,287,572		2,287,572		1,909,764
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price									$ 6.15		$ 6.15		$ 6.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											8 years 299 days		9 years 43 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate									0.00%	0.00%	0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options									$ 4,109,000		$ 4,109,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition											3 years 14 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											420,985
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											7,730
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value											$ 30,785	$ 5,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%
Two Thousand Five Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance									1,892		1,892
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									1,892		1,892
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price									$ 116.29		$ 116.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											83 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									38,378		38,378
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price									$ 10.49		$ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											5 years 138 days
The 2013 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance									143,110		143,110
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum											10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent											110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	523,209
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,523,209													2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number									2,247,302		2,247,302
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price									$ 5.98		$ 5.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											8 years 324 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period											4 years
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value									$ 3.31	$ 3.17	$ 2.56	$ 3.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									185,250	28,750	415,110	158,017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											7,730	3,020
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value									$ 5.11		$ 5.11
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									5,875	0	5,875	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period											0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number									6,250		6,250
The 2013 Plan [Member] | Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period						89
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				39,405
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period								39,494
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value								$ 6.24
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			4,797		6,544		5,998
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			4,797		6,544		5,998
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 7.07		$ 5.91		$ 7.89
The 2013 Plan [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period						25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 7.58
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						1 year
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period											5 years
The 2013 Plan [Member] | Quarterly [Member] | Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period											18,750
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%

Note 8 - Summary of Stock Opt35

Note 8 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Options outstanding, Shares (in shares) | shares	1,909,764
Options outstanding, Weighted average exercise price (in dollars per share) | $ / shares	$ 6.19
Options outstanding, Weighted average exercise priceod (in dollars per share) | $ / shares	$ 6.15	$ 6.19
Options outstanding, weighted average remaining contractual term (Year)	8 years 299 days	9 years 43 days
Options outstanding, Aggregate Intrinsic Value | $	$ 3,290,039,000	$ 211,396
Options granted, Shares (in shares) | shares	420,985
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares) | shares	2,135,320
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 6.17
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	8 years 288 days
Vested and exercisable and expected to vest, end of period, Aggregate Intrinsic Value | $	$ 3,076,175,000
Options granted, Weighted average exercise price (in dollars per share) | $ / shares	$ 5.88
Options exercised, Shares (in shares) | shares	(7,730)
Options exercised, Weighted average exercise price (in dollars per share) | $ / shares	$ 4.02
Options canceled, Shares (in shares) | shares	(35,447)
Options canceled, Weighted average exercise price (in dollars per share) | $ / shares	$ 5.64
Options outstanding, Shares (in shares) | shares	2,287,572	1,909,764
Vested and exercisable, end of period, Number Of Shares (in shares) | shares	603,985
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 6.83
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	7 years 343 days
Vested and exercisable, end of period, Aggregate Intrinsic Value | $	$ 935,383,000

Note 8 - Summary of Stock Opt36

Note 8 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.15
Options outstanding, weighted average remaining contractual term (Year)	8 years 299 days
Options exercisable, number exercisable (in shares) | shares	603,985
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.83
Options outstanding, number (in shares) | shares	2,287,572
Range One [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.64
Options outstanding, weighted average remaining contractual term (Year)	7 years 317 days
Options exercisable, number exercisable (in shares) | shares	6,771
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Options outstanding, number (in shares) | shares	12,500
Range Two [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.76
Options outstanding, weighted average remaining contractual term (Year)	7 years 222 days
Options exercisable, number exercisable (in shares) | shares	39,011
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.76
Exercise price range, lower limit (in dollars per share)	3.68
Exercise price range, upper limit (in dollars per share)	$ 3.76
Options outstanding, number (in shares) | shares	66,876
Range Three [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.62
Options outstanding, weighted average remaining contractual term (Year)	8 years 211 days
Options exercisable, number exercisable (in shares) | shares	141,577
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.78
Exercise price range, lower limit (in dollars per share)	4.46
Exercise price range, upper limit (in dollars per share)	$ 4.92
Options outstanding, number (in shares) | shares	427,829
Range Four [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.22
Options outstanding, weighted average remaining contractual term (Year)	9 years 175 days
Options exercisable, number exercisable (in shares) | shares	75,491
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.22
Options outstanding, number (in shares) | shares	586,409
Range Five [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 6
Options outstanding, weighted average remaining contractual term (Year)	8 years 171 days
Options exercisable, number exercisable (in shares) | shares	209,161
Options exercisable, weighted average exercise price (in dollars per share)	$ 6
Options outstanding, number (in shares) | shares	557,753
Range Six [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.35
Options outstanding, weighted average remaining contractual term (Year)	8 years 124 days
Options exercisable, number exercisable (in shares) | shares	43,466
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.35
Exercise price range, lower limit (in dollars per share)	6.24
Exercise price range, upper limit (in dollars per share)	$ 6.40
Options outstanding, number (in shares) | shares	117,965
Range Seven [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.67
Options outstanding, weighted average remaining contractual term (Year)	9 years 131 days
Options exercisable, number exercisable (in shares) | shares	42,593
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.70
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Options outstanding, number (in shares) | shares	472,325
Range Eight [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	5 years 146 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, number (in shares) | shares	38,135
Range Nine [Member]
Options outstanding, weighted average exercise price (in dollars per share)	$ 83.66
Options outstanding, weighted average remaining contractual term (Year)	120 days
Options exercisable, number exercisable (in shares) | shares	7,780
Options exercisable, weighted average exercise price (in dollars per share)	$ 83.66
Exercise price range, lower limit (in dollars per share)	56
Exercise price range, upper limit (in dollars per share)	$ 296
Options outstanding, number (in shares) | shares	7,780

Note 8 - Summary of Stock Opt37

Note 8 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Expected term (in years) (Year)	5 years	5 years	5 years	5 years
Average volatility	48.00%	47.00%	48.00%	65.00%
Risk-free interest rate	1.76%	1.26%	1.90%	1.53%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Note 8 - Summary of Stock Opt38

Note 8 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Allocated share-based compensation expense	$ 455	$ 202	$ 827	$ 390
Cost of Sales [Member]
Allocated share-based compensation expense	4		7
Research and Development Expense [Member]
Allocated share-based compensation expense	57	28	108	49
Selling, General and Administrative Expenses [Member]
Allocated share-based compensation expense	$ 394	$ 174	$ 712	$ 341

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%	0.00%	0.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent					0.00%

Note 10 - Related Party Trans40

Note 10 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	Oct. 04, 2007	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Stock Issued During Period, Shares, New Issues	37,500
Related Party Transaction, Amounts of Transaction		$ 1,681,000	$ 945,000	$ 3,706,000	$ 2,160,000
Accounts Payable, Related Parties, Current		$ 637,000		$ 637,000		$ 1,297,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual)	Aug. 03, 2017USD ($)
Subsequent Event [Member] | InControl Medical [Member]
Planned Equity Investment	$ 2,500,000